Journal
MEDICAL JOURNAL OF AUSTRALIA
Volume 175, Issue 9, Pages 486-+Publisher
AUSTRALASIAN MED PUBL CO LTD
DOI: 10.5694/j.1326-5377.2001.tb143683.x
Keywords
-
Categories
Ask authors/readers for more resources
Myopathy occurs in 0.1%-0.2% of patients receiving statins in clinical trials. This adverse effect is shared by all statins, but is more common with cerivastatin, especially in combination with gemfibrozil. The risk of myopathy is increased by: the use of high doses of statins concurrent use of fibrates concurrent use of hepatic cytochrome P450 inhibitors acute viral infections, major trauma, surgery, hypothyroidism and other conditions. Statin-associated myopathy should be suspected when a statin-treated patient complains of unexplained muscle pain, tenderness or weakness. Statin therapy should be stopped in cases of suspected myopathy, and serum creatine kinase levels should be checked and monitored. No specific therapies other than statin withdrawal and supportive measures for rhabdomyolysis are currently available.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available